Please ensure Javascript is enabled for purposes of website accessibility Healthcare: alive and well
uk
en
intermediary
intermediary
false
true
Gathering data
Disclaimer Not Available

Healthcare: alive and well

Healthcare: alive and well

The outlook for the healthcare sector remains positive despite its recent challenges, says Walter Scott client investment manager George Dent.

noimage


    Key points:

  • Healthcare appeals to quality growth investors due to its strong structural tailwinds, low economic cyclicality and resilient growth characteristics.
  • Performance has suffered since the pandemic due to operational disruptions and weak market communication.
  • But structural drivers persist, such as ageing populations, rising cancer incidences and changing diets.
  • Edwards Lifesciences, a pioneer in artificial heart valves, is an example of a healthcare company that is adapting and future facing.
  • Looking ahead, near-term patience is needed, but there are multiple under-recognised healthcare businesses offering opportunities for quality growth investors.
     


2934559 Exp:  3 April 2026

RELATED CONTENT
Are U.S. Equity Valuations Too Rich?
Article | Equities

With the S&P 500® hitting new highs, investors question if fundamentals or hype is fueling the rally. Despite uncertainty, the S&P 500 has delivered strong performance year to date. Its price-to-earnings (PE) ratio now sits at 22x above the nearly 17x long-term average. To some, that screams “overvalued,” but context matters.

expanding-the-investment-universe-in-global-infrastructure-tile-580x325px
Article | Equities

BNY Investments Newton’s investment strategists Brian Blongastainer and Carolina Ortega explain why they expect to see a major acceleration in global infrastructure spending over the next decade, driven by new investment opportunities fuelled by the growth in artificial intelligence (AI).

Assessing Europe's labelled bond market
IFMH | Fixed Income

In this video, Fabien Collado, portfolio manager of the Responsible Horizons Euro Corporate Bond strategy, shares his thoughts on the evolution of labelled bonds in Europe and explains why robust due diligence is integral to spotting and validating opportunities

Gathering data
Disclaimer Not Available

This is a marketing communication